| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/11/2023 | -11.35% | Cantor Fitzgerald | → $5 | Reinstates | → Neutral |
| 07/13/2022 | -82.27% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 77.3% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -82.27% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -55.67% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -46.81% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -78.72% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -11.35% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 165.96% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | 6.38% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 378.72% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 95.04% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
What is the target price for TherapeuticsMD (TXMD)?
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on January 11, 2023. The analyst firm set a price target for $5.00 expecting TXMD to fall to within 12 months (a possible -11.35% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TherapeuticsMD (TXMD)?
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD their neutral rating.
When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on January 11, 2023 so you should expect the next rating to be made available sometime around January 11, 2024.
Is the Analyst Rating TherapeuticsMD (TXMD) correct?
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $5.64, which is out of the analyst's predicted range.